Afelimomab
Based on 1 Customer Validation
Afelimomab (MAK 195F) is an anti-tumor necrosis factor monoclonal antibody. Afelimomab can be used for the research of sepsis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.34%
- CAS No.: 156227-98-4
- 분자량:145.82 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
F(ab')2-G3-kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNF
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1.5X106 RAW264.7 cells treated with 1µg/mL LPS for 24h with Afelimomab (HY-P99425, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 156227-98-4
-
Appearance Liquid
-
분자량 145.82 kDa
-
Color Colorless to light yellow
-
SMILES
[Afelimomab]
-
Synonyms
MAK 195F
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
순도&문서
-
Data Sheet (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)